What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call

Impact · against what's priced in

HALO gains a catalyst from the Dutch court ruling against Merck, as the price did not previously account for a specific European royalty stream or settlement leverage regarding KEYTRUDA QLEX. For MRK, the ruling creates a distribution headwind in Europe, though this is a marginal impact relative to the Keytruda revenue base the market already assumes. Guidance raises for HALO are largely neutral as the price already incorporates recent beats and raised outlooks.

HALO+0.40

Challenges what's priced in

The price assumes